secwatch.observer — SEC 8-K summary
======================================

Issuer:     Penumbra Inc (PEN)
CIK:        0001321732
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001321732-24-000086
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Penumbra Q2 revenue $299.4M (+14.5%); loss from ops $81M on $110.3M impairment charges
--------------------------------------------------------------------------------

- U.S. thrombectomy revenue $153.7M, up 24.9% YoY; global thrombectomy revenue $203.5M (+25.2%).
- GAAP operating loss $81.0M includes $110.3M non-cash impairment/write-down on Immersive Healthcare assets.
- Non-GAAP income from operations $31.7M vs $20.3M YoY; adjusted EBITDA $46.3M (15.5% margin).
- Cash/marketable investments increased $26.2M from Q1, driven by non-GAAP profitability and working capital.
- Global embolization & access revenue fell 3.1% YoY to $95.9M, with international down 10.8%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1321732/000132173224000086/0001321732-24-000086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1321732/000132173224000086/pen-20240730.htm
  HTML page:      https://secwatch.observer/filing/0001321732-24-000086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer